Showing 131-140 of 7650 results for "".
FDA Approves Axillary Hyperhidrosis Treatment; Study Examines Biologic Outcomes in Psoriasis
https://practicaldermatology.com/series/dermwire-tv/fda-approves-axillary-hyperhidrosis-treatment-study-examines-biologic-outcomes-psoriasis/26562/In this week's DermwireTV, the FDA approves a first-of-its-kind gel for axillary hyperhidrosis; a new analysis examines how smoking, BMI, and age affect biologic outcomes in psoriasis; and the CEO of Aerolase joins us to discuss the latest trends in the aesthetic laser market.Global Aesthetics Trends: 5 Take-aways
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/global-aesthetics-trends-5-take-aways/23795/New data on the global aesthetics market show there’s expansion in sheer patient volume as well as in who is seeking cosmetic treatments.How to Plan a Dermatology Online Marketing Campaign that Works
https://practicaldermatology.com/topics/practice-management/marketingcampaign/18293/This Ekwa Marketing video outlines the method of coming up with an effective dermatology content marketing campaign. It also discusses the various tools that can help in this.Content Marketing
https://practicaldermatology.com/topics/practice-management/content-marketing/18316/Native advertising can help overcome shortcomings in your dermatology content distribution. This Ekwa Marketing video shows you how to do this.Dermatology Marketers Should Optimize Videos for Better Results
https://practicaldermatology.com/topics/practice-management/videocontent/18323/Creating video content is important for the promotion of your dermatology practice and it's time to start, if you haven't already done so. This Ekwa Marketing video explains how you can do this and achieve higher search rankings for your dermatology videos and integrate video marketing successfullyElections and Markets, Encore and Biofrontera Launches, More
https://practicaldermatology.com/topics/practice-management/dermwiretv-elections-and-markets-encore-and-biofrontera-launches-more/18564/Election years bring market uncertainty, but should you be making any changes to your portfolio now? Financial experts weigh in on why—no matter the results—there's no need for panic. Allergan launches a new campaign, ActuallySheCan, to empower young women. Several new products are now available forRepresentation in Marketing and Outreach
https://practicaldermatology.com/series/diversity-and-equity-in-dermatology/representation-in-marketing-and-outreach/19916/There is an apparent low rate of participation in aesthetic procedures among patients of color. Does this reflect a lack of interest or does limited representation in marketing and educational materials leave patients feeling that aesthetic interventions aren't meant for them? Panelists discuss theTaking “picture perfect” before and after photos
https://practicaldermatology.com/topics/practice-management/taking-picture-perfect-before-and-after-photos/19751/You probably know the importance of including before and after photos on your dermatology website. However, you might be wondering how to create a professional looking image gallery without a photographer on call. Check out the latest video from Ekwa Marketing to find out!A Growing Armamentarium for Psoriasis: How to Choose the Right Treatment for Each Patient
https://practicaldermatology.com/topics/psoriasis/a-growing-armamentarium-for-psoriasis-how-to-choose-the-right-treatment-for-each-patient/18214/Erin Boh, MD joins host Joshua Zeichner, MD in this edition of DermTube Journal Club to offer tips for navigating all the new and existing treatment options for patients with moderate to severe psoriasis. With so many effective options on the market, Dr. Boh says it's possible to find the best fit fDupixent, Juvéderm Vollure XC, Bavencio Approvals
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-dupixent-juv-derm-vollure-xc-bavencio-approvals/18698/The FDA has approved Regeneron's injectable Dupixent (dupilumab) to treat adults with moderate-to-severe eczema. It will be marketed by Regeneron and Sanofi Genzyme in the US. Allergan's Juvéderm Vollure XC has received FDA approval based on a pivotal clinical trial in which 59 percent of subjects s